Becton, Dickinson and Company BDX
- Market cap
- $48.8B
- P/E
- 55.4×
Follow BDX
Becton, Dickinson and Company (BDX) Free cash flow
Becton, Dickinson and Company's free cash flow for fiscal 2025 was $2.7B, down 14.4% from $3.1B in fiscal 2024. Over the twelve months to 30 June 2026 it was $3.2B. Over the past ten years it has ranged from $1.1B (fiscal 2015) to $3.1B (fiscal 2024); the current reading is higher than 82% of that period. Becton, Dickinson and Company ranks 2nd of 55 Medical Instruments & Supplies companies by free cash flow.
Free cash flow, annual
Annual
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | $2.7B | (14.40%) |
| FY2024 | $3.1B | 47.40% |
| FY2023 | $2.1B | 41.26% |
| FY2022 | $1.5B | (48.91%) |
| FY2021 | $2.9B | 35.24% |
| FY2020 | $2.2B | (8.64%) |
| FY2019 | $2.4B | 20.46% |
| FY2018 | $2.0B | 8.06% |
| FY2017 | $1.8B | (2.30%) |
| FY2016 | $1.9B | 64.55% |
Quarterly
| Period | Free cash flow | Change |
|---|---|---|
| Jun 2026 | $633.0M | 15.93% |
| Mar 2026 | $546.0M | (0.55%) |
| Dec 2025 | $549.0M | (62.78%) |
| Sep 2025 | $1.5B | 59.46% |
| 42 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| ISRG Intuitive Surgical, Inc. compare | $3.3B |
| BDX Becton, Dickinson and Company | $3.2B |
| MDLN Medline Inc. compare | $2.3B |
| RMD ResMed Inc. compare | $1.6B |
| ALC Alcon compare | $1.6B |
| BAX Baxter International Inc. compare | $815.0M |
| WST West Pharmaceutical Services, Inc. compare | $436.9M |
| RGEN Repligen Corporation compare | $110.3M |
| SOLV Solventum Corporation compare | −$118.0M |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)
More on BDX
- Revenue
- Net income
- EBITDA
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement